Article thumbnail

Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes

By Trine B Opstad, Alf Åge Pettersen, Thomas Weiss, Harald Arnesen and Ingebjørg Seljeflot
Topics: Original clinical investigation
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2003). [Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes]. Rev Esp Cardiol
  2. (2000). A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haemost
  3. (1999). A: Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis
  4. (1992). Abildgaard U: The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis
  5. (2007). AK: Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose.
  6. (1989). Broze GJ Jr: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature
  7. (1999). Colocalization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.
  8. (1997). Diabetes as a risk factor for myocardial infarction: population and gender perspectives.
  9. (2001). Diabetes mellitus: a hypercoagulable state.
  10. (1998). Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost
  11. (1999). et al.: Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: impact of the V264 M substitution on plasma levels of TFPI. Arterioscler Thromb Vasc Biol
  12. (2007). et al.: Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost
  13. (2004). Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care
  14. (1995). Jr: Tissue factor pathway inhibitor. Thromb Haemost
  15. (2004). Kastrati A: Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. Atherosclerosis
  16. (1996). Kato H: Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol
  17. (1989). Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA
  18. (1999). Nemerson Y: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA
  19. (2001). Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty. Blood Coagul Fibrinolysis
  20. (2005). Sandset PM: A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost
  21. (2005). Siegbahn A: Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol
  22. (2003). Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res
  23. (1990). SP: Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.
  24. (2001). SP: Structure and biology of tissue factor pathway inhibitor. Thromb Haemost
  25. (2006). Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol
  26. (2003). Tissue factor in acute coronary syndromes. Semin Vasc Med
  27. (2004). Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J
  28. (1998). WS: Monocyte tissue factor-like activity in post myocardial infarction patients.